Skip to main content
Premium Trial:

Request an Annual Quote

Exact, OncoMethylome Pen Two-Part Deal to Sell CRC-Screening Tests, Services in Europe, N. America

NEW YORK (GenomeWeb News) — OncoMethylome Sciences and Exact Sciences today said they plan to advance the sale of stool-based colorectal cancer-screening technologies through service labs in Europe and North America. 
The agreement calls for Exact to grant OncoMethylome non-exclusive rights to its DNA-stabilization, -isolation, and -extraction technology for stool-based CRC-screening tests in Europe.
In exchange, OncoMethylome will pay royalties to Exact based on sales.
Separately, OncoMethylome will sell reagents to Exact, which may use them in stool-based CRC screening services in North America.
The reagents will enable Exact to detect methylation at certain DNA markers using MSP technology. The terms of the agreement also call for OncoMethylome to sell reagents to Exact’s commercial partners, subject to their negotiation with OncoMethylome.
Further financial details of the license and supply agreements were not disclosed. 

The Scan

Support for Moderna Booster

An FDA advisory committee supports authorizing a booster for Moderna's SARS-CoV-2 vaccine, CNN reports.

Testing at UK Lab Suspended

SARS-CoV-2 testing at a UK lab has been suspended following a number of false negative results.

J&J CSO to Step Down

The Wall Street Journal reports that Paul Stoffels will be stepping down as chief scientific officer at Johnson & Johnson by the end of the year.

Science Papers Present Proteo-Genomic Map of Human Health, Brain Tumor Target, Tool to Infer CNVs

In Science this week: gene-protein-disease map, epigenomic and transcriptomic approach highlights potential therapeutic target for gliomas, and more